CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 812 enrolled
Drug / intervention
Diagnosis of TTR amyloidosis cardiomyopathyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03842163
NCT03842163N/ACompleted
CompareCT.gov

PREVALENCE AND CHARACTERISTICS OF TRANSTHYRETIN AMYLOIDOSIS IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY OF UNKNOWN ETIOLOGY TTRACK

Pfizer·observational·Posted Feb 15, 2019·Updated Feb 12, 2024

In Brief

An observational study evaluating Diagnosis of TTR amyloidosis cardiomyopathy for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Completed, enrolled 812 participants across 18 sites in 10 countries.

Detailed Summary

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
CountriesAustralia, Austria, France, Italy, Portugal, Romania, Slovakia, Slovenia, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 15, 2019
Enrollment StartJul 9, 2018
Primary CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.4 years ago

Interventions

Diagnosis of TTR amyloidosis cardiomyopathyother

Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy